Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Q2 2022 Earnings Conference Call May 10, 2022 4:30 PM ET

Company Participants

Vince Anzalone - VP, IR

Christopher Anzalone - President and CEO

Javier San Martin - Chief Medical Officer

Ken Myszkowski - CFO

James Hamilton - SVP, Discovery and Translational Medicine

James Hassard - Chief Commercial Officer

Conference Call Participants

Maury Raycroft - Jeffries

Luca Issi - RBC Capital

Ellie Merle - UBS

Joel Beatty - Baird

Patrick Trucchio - HC Wainwright

Mayank Mamtani - B. Riley Securities

Keay Nakae - Chardan

Mani Foroohar - SVB Securities

Operator

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. Throughout today's recorded presentation, all participants will be in a listen-only mode. After the presentation, there will be an opportunity to ask questions.

I will now hand the conference call over to Vince Anzalone, Vice President of Finance and Investor Relations for Arrowhead. Please go ahead, Vince.

Vince Anzalone

Thank you Tania. And good afternoon, everyone. Thank you for joining us today to discuss Arrowhead's results for its fiscal 2022 second quarter ended March 31, 2022. With us today from management are President and CEO, Dr. Christopher Anzalone, who will provide an overview of the quarter; Dr. Javier San Martin, our Chief Medical Officer, who will provide an update -- will provide an update on our mid-and later stage clinical pipeline. Dr. James Hamilton, our Senior Vice President of Discovery and Translational Medicine will provide an update on our earlier stage program and Ken Myszkowski, our Chief Financial Officer, will give a review of the financials. We will the call up to your questions.

Before we begin, I would like to remind you that comments made during today's call contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to our SEC filings, including our most recent annual report on Form 10-K and our quarterly reports on Form 10-Q.

That said, I'd like to turn the call over to Chris Anzalone, President and CEO of the Company. Chris?

Christopher Anzalone

Thanks, Vince. Good afternoon everyone and thank you for joining us today. I want to start by saying thank you to all those who joined yesterday in Verona, Wisconsin for the ground-breaking ceremony at the site of our new manufacturing and lab facilities including Mayor Diaz, Secretary Hughes and Governor Evers.